Abstract
7537Background: More than 50% unprecedented objective clinical response rate led to a rapid approval of anti-PD-1 antibodies by FDA using in patients with relapsed/refractory classical Hodgkin lymp...
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Paper version not known
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
